Is LLY Stock Undervalued?

A comprehensive valuation analysis of Eli Lilly & Co (LLY) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated January 13, 2026•8 min read•View Full Analysis

Valuation Verdict

→

Fairly Valued

0.0% downside risk

Based on our analysis, Eli Lilly & Co appears to be fairly valued at the current price of $0.00. Our fair value estimate of $160846745910.46 suggests downside risk of approximately 0.0%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing LLY relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

N/A

P/B Ratio

N/A

P/S Ratio

N/A

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: Not currently profitable or data unavailable.
P/B Ratio: Book value data not available.
P/S Ratio: Revenue data not available.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Eli Lilly & Co stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$0.00

Fair Value Estimate

$160846745910.46

Implied Return0.0%

LLY appears fairly valued, trading within 15% of our intrinsic value estimate. The market price closely reflects the fundamental value we calculate.

Investment Conclusion

Bottom Line

Eli Lilly & Co (LLY) appears fairly valued at $0.00, trading in line with our fundamental analysis. The stock may be appropriate for investors seeking exposure to Health Care without significant valuation risk.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.